Drug heterojunction material, osteogenesis scaffold material and preparation method

Through the interface modified sound-sensitive agent, heterojunction material composed of variable valence metal substances and strontium, combined with ultrasound activation, the problems of poor antibiotic resistance, cytotoxicity and osteoinduction ability in bone defect treatment and implant infection control are solved, and efficient antibacterial and bone regeneration are achieved.

CN119656308APending Publication Date: 2025-03-21WEST CHINA HOSPITAL SICHUAN UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202411883235.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-19
Publication Date
2025-03-21

AI Technical Summary

Technical Problem

The existing bone defect treatment and implant infection control technologies have problems such as antibiotic resistance, cytotoxicity, poor osteoinduction ability, low ROS production efficiency, and possible inflammatory response, which limits the success rate of treatment and the quality of life of patients.

Method used

A drug heterojunction material is used to chelate heterojunctions composed of interfacially modified sound-sensitive agents and chelated heterojunctions with variable valence metal substances and strontium, combined with ultrasound activation to generate ROS, and induce bacterial cell death through variable valence metal substances, achieving the dual effects of antibacterial and promoting bone regeneration.

Benefits of technology

It improves ROS production efficiency, enhances antibacterial performance, reduces inflammatory response, promotes bone tissue repair, and improves the safety and effectiveness of orthopedic implants.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a drug heterojunction material, an osteogenic scaffold material and a preparation method, and belongs to the technical field of osteogenic materials. The drug heterojunction material comprises a variable valence metal substance, a sound-sensitive agent and strontium, wherein the variable-valence metal substance contains variable-valence metal elements; the drug heterojunction material is a heterojunction formed by chelating an interface-modified sound-sensitive agent and a variable-valence metal substance and loading strontium. The drug heterojunction material provided by the invention can promote the generation of ROS and realize excellent antibacterial performance under ultrasonic stimulation. After ultrasound is stopped, varied valence of metal elements can be chelated with strontium, the anti-inflammatory and anti-oxidation performance of strontium is enhanced, redundant ROS is consumed, inflammatory reaction is avoided, bone regeneration is promoted, and meanwhile the two problems of infection and repair of an osteogenic material are solved.
Need to check novelty before this filing date? Find Prior Art